Amaris Elliott Engel

July 21, 2014 | National Law Journal

As the Food and Drug Administration embarks into the brave new world of regulating marketing by the pharmaceutical industry on social media, regulators explain that companies won't be held responsible for user-generated consent that is “truly independent,” even if it is on blogs, message boards and chat rooms the companies host.

By Amaris Elliott-Engel

2 minute read

July 21, 2014 | National Law Journal

The city of Chicago and a group of pharmaceutical companies that make opioid painkillers have agreed that the city's complaint against them can be unredacted and unsealed.

By Amaris Elliott-Engel

2 minute read

July 21, 2014 | National Law Journal

The Florida Court of Appeals, First District, has upheld a judgment against two tobacco companies.

By Amaris Elliott-Engel

2 minute read

July 17, 2014 | National Law Journal

A federal judge presiding over lawsuits brought by plaintiffs alleging they were hurt or killed because of defective dialysis products has approved a qualified protective order for Health Insurance Portability and Accountability Act information.

By Amaris Elliott-Engel

2 minute read

July 17, 2014 | National Law Journal

Plaintiffs lawyers are objecting to what they call “unfounded claims” of attorney-client privilege or attorney work-product privilege for 1,800 documents produced by Merck Sharp & Dohme Corp. in litigation over male pattern hair loss drug Propecia.

By Amaris Elliott-Engel

2 minute read

July 17, 2014 | National Law Journal

The maker of safety technology for tablesaws failed to show antitrust violations by the tablesaw industry because it was not anticompetitive behavior for manufacturers to dominate a standards-setting organization in pursuit of commercial interests, a Virginia federal judge ruled.

By Amaris Elliott-Engel

2 minute read

July 16, 2014 | National Law Journal

The Food and Drug Administration is seeking a permanent injunction against the California manufacturer of over-the-counter vaginal products because regulators say the products have not been approved for safety.

By Amaris Elliott-Engel

2 minute read

July 16, 2014 | National Law Journal

A sharply divided U.S. Court of Appeals for the Fifth Circuit has ruled against consulting the Louisiana Supreme Court on whether brand-name drugmakers can face liability for generic versions of their products in the Pelican State.

By Amaris Elliott-Engel

3 minute read

July 16, 2014 | National Law Journal

The Chicago Tribune, the Los Angeles Times and USA Today have moved to intervene in the lawsuit the city of Chicago is prosecuting against pharmaceutical companies over the epidemic of opioid painkiller abuse.

By Amaris Elliott-Engel

2 minute read

July 16, 2014 | National Law Journal

Class action claims by car purchasers against their subprime lender were filed beyond the statute of limitations, the U.S. Court of Appeals for the Eighth Circuit has ruled.

By Amaris Elliott-Engel

3 minute read